Novelion Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported net revenues of $29,984,000. Loss from operations was $21,663,000 compared with $8,926,000 a year ago. Loss before provision for income taxes was $30,823,000 compared to $21,888,000 a year ago. Net loss was $30,962 against $21,894 a year ago. Basic and diluted loss per common share was $1.67 compared with $2.07 a year ago. Non-GAAP net loss was $8,687,000 compared with $70,995,000 a year ago. Non-GAAP basic loss per common share was $0.47 compared with $6.72 a year ago. Non-GAAP net revenues were $29,984,000 compared with $35,716,000 a year ago.

The company reiterated revenues guidance for full year 2017. For the year 2017, the company expects total net revenues to be between $155 million and $165 million.